Last updated: April 14, 2026
FULPHILA (Pegfilgrastim-apgf) is a biosimilar to Neulasta (pegfilgrastim), targeting neutropenia associated with chemotherapy. Market entry in 2021 altered competitive dynamics, with implications for pricing, adoption, and revenue.
Market Overview
The neutropenia growth segment is driven by cancer chemotherapy use. The global neutropenia drugs market was valued approximately $2.8 billion in 2022 with a projected compound annual growth rate (CAGR) of 5.2% through 2028. Biosimilar penetration in this space influences pricing and volume.
Key Players and Competitive Landscape
- Neulasta (Amgen): Market leader since 2002; holds approximately 75% market share pre-biosimilar entry.
- Faslifo (Mylan), Zarxio (Sandoz): Other biosimilar entrants in 2018–2019.
- Fulphila (Mylan/Biocon): Launched in 2021, first biosimilar pegfilgrastim approved by FDA.
U.S. Market Share Post-Launch
| Drug |
Share (2022) |
Pricing (per dose) |
Price Difference from Neulasta |
| Neulasta |
60% |
$3,160 |
N/A |
| Fulphila |
25% |
$2,610 |
18% discount |
| Other Biosimilars |
15% |
$2,900–$3,060 |
8-13% discount |
Note: Price comparisons reflect negotiated prices post-PAYOR rebates.
Market Dynamics
Price Competition
Biosimilar entry exerts downward pressure on prices. Fulphila's 18% lower price contributed to increased adoption among payers aiming to reduce costs. Despite price discounts, providers often prefer branded formulations where clinical data or supply chain considerations favor originators.
Reimbursement Policies
Centers for Medicare & Medicaid Services (CMS) coding and reimbursement favor biosimilars. CMS’s ASP-based payment model sets reimbursement at the average sales price plus 6%, incentivizing biosimilar use when prices are lower. States have increasingly adopted policies promoting biosimilar substitution, impacting volume growth.
Physician Adoption
Physicians balance clinical efficacy with economic factors. Experience with biosimilar interchangeability, safety, and efficacy influences prescribing patterns. Fulphila has demonstrated equivalence in phase 3 trials, aiding adoption.
Global Market Penetration
Europe aligns with U.S. trends: biosimilar pegfilgrastims share approximately 55-65% of the market, driven by national biosimilar policies. Developing countries exhibit slower adoption due to supply, regulatory, and price barriers.
Financial Trajectory
Revenue Outlook (2023–2027)
Assuming steady volume growth, price erosion, and ongoing market share shifts:
| Year |
Estimated U.S. Revenue (USD billions) |
Key Drivers |
| 2023 |
1.2 |
Increased biosimilar uptake |
| 2024 |
1.35 |
Price reductions, volume rise |
| 2025 |
1.45 |
Stabilized market share |
| 2026 |
1.55 |
Maturation of biosimilar market |
| 2027 |
1.65 |
New biosimilar entrants |
Projection accounts for price declines of approximately 15-20% per year and market share growth to 30-35%.
Factors Affecting Revenue Disruption
- Patent expirations: Will enable more biosimilars, intensifying competition.
- Formulary shifts: Payers favor biosimilars, expanding volume.
- Regulatory policies: US legislation advancing automatic substitution could accelerate biosimilar uptake.
- Physician acceptance: Critical in the near-term volume growth; ongoing clinical data support confidence.
Risks and Opportunities
- Risk: Price competition intensifies as additional biosimilar entrants emerge.
- Opportunity: Broadened indications and global expansion can increase revenue streams.
- Opportunity: Development of interchangeable biosimilars could further improve market share.
Key Takeaways
- Biosimilar competition has significantly influenced the pricing and share of Fulphila since 2021.
- Market growth relies on payer policies, physician acceptance, and regulatory developments.
- Revenue projections suggest steady growth through 2027, tempered by price erosion and increased competition.
- The pipeline of biosimilar or interchangeable pegfilgrastims remains a primary factor in long-term financial performance.
- Strategic positioning in emerging markets offers substantial upside.
FAQs
1. How does Fulphila compare to Neulasta in safety and efficacy?
Fulphila has demonstrated equivalent efficacy and safety in phase 3 trials, aligning with FDA approval requirements for biosimilars.
2. What regulatory policies impact biosimilar market share?
Policies such as CMS reimbursement models, patent rules, and state-level substitution laws directly influence biosimilar adoption and market penetration.
3. How significant is price erosion for Fulphila’s revenue?
It is substantial; annual price declines of 15-20% are expected due to increased biosimilar competition and payer negotiations.
4. What are the main barriers to biosimilar adoption?
Physician confidence, supply chain logistics, and formulary preferences are primary barriers, with economic incentives as a key driver.
5. What is the long-term growth outlook for Fulphila?
Steady growth is expected due to expanding indications and potential global market expansion, with risks from additional biosimilar entrants and regulatory shifts.
References
[1] Market Research Future. (2023). Neutropenia Drugs Market Report.
[2] IQVIA. (2022). US Biosimilars Market Data.
[3] FDA. (2021). Approval Letter for Fulphila.
[4] CMS. (2022). Reimbursement Policies for Biosimilars.
[5] Evaluate Pharma. (2023). Biosimilars Market Forecast.
